Tatva Chintan Pharma Chem's Q4 FY 2025-26 Quarterly Results

Result Summary

• Tatva Chintan Pharma Chem Ltd reported a 0.5% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 23.2%.
• Its expenses for the quarter were up by 1.6% QoQ and 10.0% YoY.
• The net profit decreased 31.9% QoQ and increased 901.9% YoY.
• The earnings per share (EPS) of Tatva Chintan Pharma Chem Ltd stood at 4.41 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

## Company Overview
Tatva Chintan Pharma Chem Ltd is a company operating in the chemical industry, specifically focusing on the production of specialty chemicals. The company is known for its diverse portfolio, which includes products such as structure-directing agents, phase transfer catalysts, electrolyte salts for supercapacitor batteries, and pharmaceutical intermediates. These products cater to a variety of industries, including automotive, petroleum, agrochemicals, and pharmaceuticals. As of the latest available data, the company has been involved in expanding its product lines and improving its manufacturing processes to enhance efficiency and meet growing market demands. However, specific recent developments or strategic initiatives are not detailed in the provided data.

## Revenue
In the fourth quarter of FY26, Tatva Chintan Pharma Chem Ltd reported a total income of ₹133.80 crores, reflecting a quarter-over-quarter (QoQ) increase of 0.5% from ₹133.07 crores in Q3FY26. When compared year-over-year (YoY) with Q4FY25, the total income showed a significant increase of 23.2% from ₹108.59 crores. This growth in revenue indicates a positive trend in the company's ability to generate income from its operations over the past year, despite a relatively stable quarter-over-quarter performance.

## Profitability
The profitability of Tatva Chintan Pharma Chem Ltd for Q4FY26 shows a mixed performance. The company recorded a profit before tax of ₹16.59 crores, which is a decline of 6.1% from the ₹17.66 crores reported in Q3FY26. However, on a year-over-year basis, the profit before tax surged by an impressive 717.2% from ₹2.03 crores in Q4FY25. The tax expenses increased substantially by 151.8% QoQ and 527.0% YoY, impacting the profit after tax, which was ₹10.32 crores in Q4FY26. This represents a decline of 31.9% from ₹15.16 crores in Q3FY26 but a remarkable increase of 901.9% from ₹1.03 crores in Q4FY25. Earnings per share mirrored this trend, decreasing by 32.0% QoQ to ₹4.41, yet increasing by 902.3% YoY from ₹0.44.

## Operating Metrics
The operating metrics of Tatva Chintan Pharma Chem Ltd highlight both growth and cost management aspects for Q4FY26. Total expenses amounted to ₹117.22 crores, reflecting a QoQ increase of 1.6% from ₹115.41 crores in Q3FY26 and a YoY rise of 10.0% from ₹106.56 crores in Q4FY25. The YoY increase in expenses is considerably lower than the increase in total income, indicating a degree of cost efficiency. Despite the increase in expenses, the substantial YoY improvement in profitability metrics suggests a successful year in terms of operational performance. However, the QoQ decline in profit before tax and profit after tax indicates potential challenges in maintaining quarterly profitability amidst rising expenses and tax obligations.